Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25546067 | 0.89 | RIPK2 (0.41) | LMNAMAPTDYRK1ARIPK2GRM2 | |
| SCHEMBL25180286 | 0.86 | GRM2 (0.41) | LMNAMAPTGRM2 | |
| SCHEMBL25546010 | 0.83 | XDH (0.35) | GRM2FBP1 | |
| SCHEMBL25546014 | 0.83 | ALDH1A1 (0.40) | LMNAMAPTDYRK1ARIPK2GRM2 | |
| SCHEMBL25179836 | 0.81 | BRAF (0.43) | FBP1 | |
| SCHEMBL25556500 | 0.79 | LMNA (0.38) | LMNAMAPTRIPK2GRM2 | |
| SCHEMBL25545936 | 0.79 | PAX8 (0.39) | LMNAMAPTGRM2 | |
| SCHEMBL25556504 | 0.77 | ALDH1A1 (0.37) | LMNAMAPTGRM2 | |
| SCHEMBL25546017 | 0.77 | ALDH1A1 (0.37) | LMNAMAPTGRM2FBP1 | |
| SCHEMBL25556352 | 0.76 | MEN1 (0.43) | LMNAMAPTGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | LMNA 2647/4885MAPT 2231/4885DYRK1A 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.